Importance: The effectiveness of lipid-lowering, blood pressure-lowering, and aspirin treatment for prevention of cardiovascular disease (CVD) differs between individuals with type 2 diabetes (T2DM).
Introduction
People with T2DM are at up to 2-fold increased risk for cardiovascular disease (CVD) compared to people without T2DM independently from other risk factors. 1 Estimated reductions in life expectancy and quality adjusted life years (QALYs) due to CVD are substantial in people with T2DM especially in people diagnosed with T2DM at young ages. 2 3 International guidelines on CVD prevention recommend lipid-lowering and blood pressure-lowering treatment to achieve cholesterol-and blood pressure targets.
As treatment effects may vary greatly between people due to differences in baseline risk, a more individualised approach based on absolute individual CVD-risk should be considered. [4] [5] [6] [7] [8] In general, people with higher individual cardiovascular risk will benefit more in absolute terms from lipid-lowering or blood pressure lowering than people with a lower cardiovascular risk. As these treatments are usually used lifelong, it is important to take into account long-term CVD-risk in addition to shorter term risk such as five or 10 year risk as used in many risk scores. 9 The use of CVD risk prediction models for people with T2DM, such as the UKPDS, ADVANCE, Fremantle, and New Zealand Diabetes risk scores has been recommended in various national guidelines. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Long-term CVD-risk and CVD-free life expectancy can also be estimated. The latter is the expected number of remaining life years without the occurrence of an incident or recurrent myocardial infarction or stroke, which may be more informative to patients and healthcare providers than an estimate of risk. [23] [24] [25] Most existing prediction models predict 5-year risks of CVD 12 , however, in people under 50 years of age life expectancy is usually much longer than 5 years. The treatment goal may then be to prevent CVD later in life. As 5-year CVD-risk in younger people is nearly always low, the potential longterm benefit of preventive drug-treatment is frequently underestimated. This may lead to delays in prescribing effective interventions in younger people. As age is such an important risk factor for CVD the majority of older people are eligible for treatment. However, as older people are also at risk for other diseases and mortality from both vascular and non-vascular causes (i.e. competing risks), reductions in CVD-risk may not always result in life years gained. This decreased potential to benefit from preventive treatment due to competing risks is not taken into account in existing risk models and may contribute to the over-estimation of the effect of preventive treatment in older people.
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The objective of the present study was to develop and externally validate a Diabetes Lifetime-perspective prediction (DIAL) model, for individualising lifelong CVD prevention with lipid-lowering, antihypertensive, and aspirin treatment in people with T2DM by predicting 10-year CVD-risk, CVD-free life expectancy, and treatment effects in terms of CVD-free life years gained:. Notably, CVD-free life expectancy for a person with a history of CVD should be interpreted as time without recurrent myocardial infarction or stroke.
Methods

Sources of data
The Swedish National Diabetes Registry (NDR) and the Scottish Care Information (SCI) Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) are randomised controlled trials, all including people with T2DM. Study details have been described elsewhere. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] The prediction model was developed in the Swedish NDR and externally validated in the remaining datasets. Definitions of T2DM used in each study are provided in supplemental table 1. All use of registers data, cohort and trial studies were approved by institutional review boards and all participants gave written informed consent before taking part in the cohorts and trials.
Participants
Participants were people aged >18 years with a diagnosis of T2DM with or without prevalent CVD.
People with a previous diagnosis of cancer (ICD-10 codes C00-C97) or stage 4 or 5 chronic kidney disease (estimated glomerular filtration rate, eGFR <30 mL/min) were excluded. A comprehensive overview of the eligibility criteria for the original cohorts and trials are provided in supplemental table 1.
Outcomes
CVD was defined as a non-fatal myocardial infarction, non-fatal stroke, or vascular mortality. In the Swedish NDR and the SCI -Diabetes database, this is based on linkage to cause of death registers and hospital discharge registers using ICD-10 codes (non-fatal myocardial infarction: ICD-10 code I21; nonfatal stroke ICD-10 code I61, I63, I64; vascular mortality: ICD-10 codes I20-I25, I46.0, I46.1, I46.9, I61, I63, and I64). For all cohort and trial data, the endpoint definitions are described in supplemental table 1.
There was blinding to randomisation group for assessment of outcomes in trial participants. Non-vascular mortality was defined as all deaths other than those with a cardiovascular cause identified in the above list.
Predictors
Predictors were predetermined based on existing diabetes risk scores and availability in routine clinical practice. 13-19 21 Baseline data for people registered in the Swedish NDR and SCI -Diabetes database were data collected in the first year after registration. In the other data sources, the baseline data were measured at study entrance prior to follow-up. Eleven predictors were selected; sex (female/male), current smoking (yes/no), systolic blood pressure (SBP in mmHg), body-mass index (BMI in kg/m²), haemoglobin A1c
(HbA1c in mmol/l), eGFR (ml/min), non-high-density lipoprotein cholesterol (non-HDLc in mmol/l), albuminuria (no/micro/macro), duration of T2DM (years since diagnosis), insulin treatment (yes/no), history of CVD (yes/no). Micro-albuminuria was defined as an albumin/creatinine ratio 3-30 mg/mmol or urine-albumin 20-300mg/l, and macro-albuminuria was defined as an albumin/creatinine ratio >30mg/mmol or urine-albumin >300mg/l. Prescriptions for preventive medication for CVD were not selected as a predictor, because this would interfere with the predictions of treatment effects of these medication. Socio economic status was not selected due to limited availability in many datasets.
Missing data
To account for missing data in the predictors, single imputation by predictive mean matching was used for each of the original cohorts separately (aregImpute in R, Hmisc package). 38 In the validation cohorts, some predictors were not recorded at all. For cohorts where HbA1c was not measured for any participant (i.e. ALLHAT and ASCOT), values were estimated using available plasma glucose levels assuming measured glucose levels to be average glucose levels (Glucose (mmol/l) = 1.59*HbA1c (%) -2.59, thus
HbA1c (%) = (Glucose (mmol/l)+2.59)/1.59). 39 For all other missing predictors in the validation dataset, data were imputed to the median value of the Swedish NDR. The number, proportions and type of missing data in each dataset are described in the supplemental methods.
Statistical analysis
Handling continuous predictors
Continuous predictors were truncated at the 1st and 99th percentile to limit the effect of outliers. Loglinearity of the relationship between continuous predictors and the outcomes was tested with restricted cubic splines and transformations were applied when this improved model fit based on Akaike's Information Criterion.
Development of the lifetime model
A random sample of 75% of people from the Swedish NDR (n=292,024) was used as the development dataset. Using these data, we developed two complementary Fine and Gray competing risk adjusted Cox proportional hazard models with left truncation and right censoring: one for the prediction of CVD events using non-vascular mortality as the competing endpoint (i.e. model part A), and another for the prediction of non-vascular mortality using CVD events as the competing endpoint (i.e. model part B). These statistical methods have been described in detail previously. 23 40 Briefly, age was used as the time-scale and therefore people in the development dataset contributed data to the survival model from their age at study entry until the time of an event or censoring, defined by the age at study exit. As a result, estimates derived from these models are not limited by follow-up time but by the age distribution of study participants. However, predictions are unstable where the number of people and number of events in a specific age group is limited. . The age-range was therefore limited to between 30 and 95 years (number of people <30 years: 2,045, number of people >95 years: 2,501) for estimation of CVD-free life expectancy. The two competing risk adjusted Cox proportional hazard functions were then recalibrated based on the incidence of CVD and incidence of non-vascular mortality using the expected versus observed ratio. The age-specific baseline survival for both Cox proportional hazard functions were centred for continuous variables (BMI of 30 kg/m 2 , systolic blood pressure of 140 mmHg, non-HDLc of 3.8 mmol/l, HbA1c of 50 mmol/l, and eGFR of 80 ml/min) for practical reasons and to avoid rounding errors. The proportional hazards assumption was assessed by inspection of the correlation plots between scaled Schoenfeld residuals for the various predictors and age. Transformations and non-proportionality of predictors were described in the supplemental methods. Where interaction existed between a predictor and age, the HR for that predictor is shown for the median age of 65 years. The HR for transformed predictors is shown for the 75th percentile versus the 25th percentile. The sample size was more than sufficient by conventional assessment for prediction models with >1000 endpoints per variable. 41 
Predictions for individual persons
Calculations of CVD-free life expectancy (i.e. median survival without incident or recurrent myocardial infarction, stroke, or vascular death) were based on life-tables with one-year time intervals. An example of such a life -table for an individual person is shown in supplemental table 2 . Starting at the current age of an individual with T2DM, the risk of having a CVD-event (at) and the risk of dying from non-vascular causes (bt) were predicted for each future life-year. Next, the cumulative CVD-free survival (Survt+1) was calculated by multiplying the survival probability at the beginning of each life-year (Survt) by the CVDfree survival probability during that year (Survt -at -bt). Obviously the cumulative CVD-free survival started at 100% at the current age of a person. This process was repeated until the maximum age of 95 years. CVD-free life expectancy of an individual was defined as the median survival without myocardial infarction or stroke or death, which was the age where the estimated cumulative survival drops below 50%. Similarly, 10-year CVD-risk was calculated by summation of the predicted cause-specific CVD risk in the first 10 years from a person's current age onwards. The cause-specific CVD-risk was obtained by multiplication of the chance of survival without a CVD-event at the beginning of each year (Survt) and the risk of having a CVD-event (at) during that year.
Model validation
Internal validation of the lifetime model was performed in the remaining random sample of 25% of people in the Swedish NDR (n=97,342) for 10 year risk predictions. External validation was performed using pooled cohorts based on geographical origin of people originating from the SCI -Diabetes database, SMART, EPIC-NL, ACCORD, ADVANCE, ASCOT, and ALLHAT cohorts. The selected regions were continents, with a subdivision for Europe. Five-year risks were predicted for Western-Europe, EasternEurope, North-America, Asia and Oceania, and 10 year risks for Scotland. Although Scotland is part of Western-Europe, this was a separate validation dataset, due to both the longer follow-up and the population-based nature of the dataset. In addition, the comparatively large number of people in Scotland's diabetes register overwhelmed the number of people in other countries in Western-Europe.
Supplemental table 3 presents the number of people allocated from each original cohort to each pooled geographical cohort and the number of events occurred in each pooled cohort.
Goodness of fit was assessed for CVD-free survival, vascular event, and non-vascular mortality models separately using calibration plots. 42 The models were recalibrated based on the incidence of CVD and incidence of non-vascular mortality using the expected versus observed ratio in all separate datasets. The logarithm of the expected versus observed ratio was subtracted from the linear predictor. Discrimination was quantified using c-statistics.
Prediction of individual treatment effect
We combined competing risk adjusted Cox proportional hazard function A for prediction of CVD with hazard ratios from randomised trials or meta-analyses to predict the individual treatment effect and lifetime benefit of treatment. This method of calculating projected individual treatment effects has previously been applied by the American Heart Association and American College of Cardiology in their 'ASCVD risk estimator plus' based on the Pooled Cohort Equations for primary prevention. 43 By using life-tables, any gains in CVD-free survival will automatically be adjusted for competing risks by increasing the time at risk for non-CVD mortality. In this study, we derived estimates of the effect of lipid-lowering, blood pressure-lowering, and aspirin treatment. [44] [45] [46] [47] [48] [49] The hazard ratios for different medications used to estimate treatment effects are described in the supplemental methods. The lifetime benefit of treatment for an individual person was calculated as the difference between the predicted median CVD-free life expectancy with and without treatment. Similarly, 10-year absolute CVD-risk reduction for individual persons were estimated by calculating the difference between the predicted 10-year CVD-risk with and without treatment.
Results
The selection of development and validation cohorts from the Swedish NDR is illustrated in figure 1 
Internal validation
After recalibration for differences in predicted and observed non-vascular death rates predicted 10-year risk for CVD and all-cause mortality (CVD risk and non-vascular mortality risk combined) showed good agreement with the 10-year observed risk in the development dataset (figure 2). Discrimination of the 
External validation
The predicted 5-year risk for CVD and all-cause mortality showed good agreement with the observed 5-year CVD-free survival in Western-Europe, Eastern-Europe, North-America and Asia and Oceania 
Discussion
In this study we have developed and validated the DIAL model to predict CVD-free life expectancy and 10-year CVD risk in people with T2DM using widely available patient characteristics. This is the first model for people with T2DM that predicts 10-year CVD risk, CVD-free life expectancy, and lifetime benefit in CVD-free life years gained. This enables the identification of likely long-term benefit of preventive treatment for people with T2DM. By taking into account the competing risk of non-CVD mortality, the model can reliably estimate treatment effects. Therefore, the DIAL-model offers additional functionality compared to existing risk scores for people with T2DM (i.e. mainly 5-year absolute risk for people with T2DM) that tend to underestimate risk and benefits of treatment in younger people and overestimate risk and benefits in older people. 13-19 21 Increasing incidence of T2DM in younger people and the marked increases in prevalence of type 2 diabetes in elderly people means that assessing CVD risk accurately and treating it appropriately is essential for individuals, health systems and societies.
We Rotterdam Study showed that the gain in total CVD-free life expectancy increased as risk factor levels increased. The gain in total CVD-free expectancy decreased with advancing age, whereas 10-year risk for CVD mortality, and therefore 10-year risk reduction, increased with age. 50 In other primary prevention settings, the gains from preventive therapy for CVD have been largest in younger people with high lifetime risk for CVD due to high risk factor levels. 23 24 51 For example, smoking cessation at age 60, 50, 40, or 30 years resulted in about 3, 6, 9, and 10 years of life years gained respectively. This indicates that the highest lifetime benefit can be gained by reducing risk factors early in life, ideally with lifestyle interventions but, if necessary, with drug treatment. 52 We illustrate this with our model in figure 3 . A younger patient with high risk factor levels (Patient A) has the potential to benefit more from preventive therapy on the long term compared to an older patient with lower risk factor levels (Patient C), despite the fact that 10-year absolute risk reduction is higher for the older patient in this example.
In clinical practice, prediction of lifetime benefit in CVD-free life years gained would enable patients (as well as clinicians) to better understand the potential benefits of treatment. Such information could help patients to participate in the decision-making process about treatment and may also motivate them to adhere to therapy. Clinicians and patients can balance the benefit and possible disadvantages of treatment,
to decide whether preventive medication should be started or stopped. Also, the ability to estimate which preventive therapy is most effective (e.g. lipid-lowering, blood pressure-lowering or aspirin treatment)
can help to decide what treatment should be initiated first, and what treatment can be postponed or not prescribed to avoid excessive polypharmacy.
Using the concept of predicting lifetime benefit for making treatment decisions will result in changing characteristics of people eligible for treatment, towards higher proportions of younger people with higher risk factor levels (figure 4). This group of people need to be treated over a longer period of time resulting in higher treatment costs. It is not clear whether stopping treatment in older people would offset these costs and health economic analyses are required to investigate and to establish appropriate thresholds of minimum gain in life-years free of CVD The strengths of this study include the use of a large number of people from diverse cohorts. Since the Swedish and SCI -Diabetes database are registries with information for over 90% of people with T2DM in both countries, there is limited selection of people with T2DM, in contrast to trial populations. Clearly prediction of effects of lifestyle interventions would be valuable. However, it is currently not feasible to include lifestyle factors in prediction models given the lack of robust estimates of the effect size for lifestyle interventions from randomised controlled trials.
Other limitations of the methods used to develop and validate the DIAL model, and to estimate treatment effects should be acknowledged. Baseline predictors such as duration of T2DM, albuminuria, insulin treatment, and HbA1c were missing for some people within the validation data. The use of median, surrogate, and assumed values for these predictors could lead to the underestimation of the accuracy of the model if all data were available. However such data are often missing in clinical practice and prediction tools need to have alternative approaches available for them to be useful in the real world.
Second, validation could only be performed for 10-year and 5-year predictions due to the limited followup in the included cohorts and trials. Lifetime estimates often go beyond 10-year predictions, and require the assumption that rates will be similar for a current 40 year old in 40 years' time to those of an 80 year old today. This is a major assumption but previous studies have shown that lifetime estimates based on the methods we used appear to apply for a survival of up to 17 years. 23 Nevertheless, longer-term validation would be preferable and will be possible as follow up data accrue in Sweden and Scotland.
Third, a 5-10% overestimation of predicted risk of CVD and mortality combined was observed in people in the highest decile of risk in most external validation datasets. However, in clinical practice, this may not be too problematic, since these people are at high risk anyway and the overestimation does not result in misclassification or incorrect treatment decisions. Furthermore, possible changes in risk factor levels over time were not taken into account. For example, blood pressure and cholesterol were assumed to remain stable over time. Also, the lifetime benefits are calculated assuming immediate, lifelong, successful (i.e. targets reached) and uninterrupted treatment from their current age onwards. Therefore, re-evaluation of CVD-free survival and treatment effects after 5 to 10 years is advised based on our validation to ensure valid predictions to guide treatment decisions.
In conclusion, CVD-free life expectancy as well as the effect of lifelong lipid-lowering, blood pressurelowering, and aspirin treatment in terms of CVD-free life years gained can be reliably predicted for people with T2DM using readily available characteristics. The DIAL model may facilitate personalised treatment and support shared decision-making and patients' motivation to adhere to prescribed drugtreatments to reduce CVD risk.
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In the Swedish National Diabetes Registry (NDR) proportions of missing data was 0% for age, sex, and outcome status, 15% for systolic blood pressure (SBP), 11% for Hemoglobin A1c (HbA1c), 12% for duration of T2DM, 22% for smoking status, 25% for body mass index (BMI), 21% for estimated glomerular filtration rate (eGFR), 31% for total cholesterol, 40% for high-density lipoprotein cholesterol (HDLc) and 42% for albuminuria. In the SCI -Diabetes database proportions of missing data were 0% for age, sex, and outcome status, 9% for SBP, 10% for HbA1c, 12% for eGFR, 22% for smoking status, 32%
for non-HDLc, 35% for BMI, and 43% for albuminuria. Duration of T2DM was not missing, because the population was limited to an incident cohort. In SMART missing data for cholesterol, eGFR, history of CVD and albuminuria ranged from 0.05% to 6%. In EPIC-NL missing data was 1% for SBP and history of CVD, 3.6% for duration of T2DM, 11.5% for HbA1c, eGFR, cholesterol, HDLc, and 24.8% for type of diabetes treatment. In the ACCORD and ADVANCE-trial, missing data ranged from <1% for SBP to 4.5% for albuminuria. In the ASCOT-trial missing data was 8.3% for plasma glucose and 33.6% for eGFR. In the ALLHAT-LLT-trial missing data was <2.0% for BMI, cholesterol, HDLc, and eGFR, and 20.9% for plasma glucose.
In EPIC-NL, ASCOT, and ALLHAT-LLT, data was not available for duration of T2DM (ASCOT, ALLHAT-LLT), albuminuria (EPIC-NL, ALLHAT-LLT), treatment of T2DM with insulin (ASCOT, ALLHAT-LLT) and HbA1c. For validation, duration of T2DM, treatment with insulin, and albuminuria were imputed by the median values in Swedish NDR (i.e. 2.0 years duration of T2DM, 17% insulin treatment, 15% micro-albuminuria, and 7% macro-albuminuria).
Transformations and non-proportionality of predictors.
Quadratic transformation of continuous predictors was applied for BMI, SBP, HbA1c, non-HDL-c and eGFR for the CVD Cox proportional hazard function and for BMI, SBP, and BMI for the non-vascular mortality Cox proportional hazard function. Non-proportionality was observed for sex, smoking, history of CVD and treatment with insulin, in both parts of the Cox proportional hazard functions (i.e. for CVD and non-vascular mortality). These predictors are of increasing or decreasing importance with increasing age. Therefore, interactions with these predictors and age were included in the model. Supplemental figure 1 (CVD) and supplemental figure 2 (non-vascular mortality) visualize the HRs of transformed predictors and HRs of predictors depending on age.
Relative treatment effects of meta-analyses and trials translated to lifelong treatment benefit in CVD-free life years gained.
Lipid-lowering treatment:
The effect of lipid-lowering treatment on CVD depends on estimated reduction in low-density lipoprotein cholesterol (LDLc) compared to baseline. A reduction of 1 mmol/l LDLc is related to a hazard ratio of 0.78. 44 45 The percentage decrease of baseline LDLc for different statins and/or ezetimibe for people with T2DM are described in meta-analyses. 47 48 The individual expected relative risk reduction of CVD is calculated by 0.78
, where LDL-reduction in mmol/l is defined as Baseline LDL-c multiplied by the expected percentage LDL-c reduction due to intended treatment.
Blood pressure-lowering treatment:
The effect of blood pressure-lowering treatment is estimated as a hazard ratio of 0.74 per 10 mmHg for people with T2DM with a baseline blood pressure of 140mmHg or higher. 46 There is no relative risk reduction assumed of lowering blood pressure under 140 mmHg. 49 The individual expected relative risk reduction of CVD is calculated by 0.74 (Blood pressure reduction in mmHg/10) , where blood pressure reduction in mmHg is the blood pressure of the patient minus the target blood pressure. This only applies for people with a blood pressure above 140 mmHg. The hazard ratio for blood pressure changes under 140mmHg is assumed to be 1.
Aspirin treatment:
The effect of aspirin treatment on CVD differs between people with and without a history of CVD. The hazard ratio of aspirin treatment in people without a history of CVD is 0.88 and for patient with a history of CVD 0.81.
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Combined individualized treatment effects:
The hazard ratios of lipid-lowering, blood pressure-lowering, and aspirin treatment are multiplied to calculate the relative individualized risk reduction for the combination of treatments. This hazard ratio of intended treatment is used in the Cox proportional hazard function for vascular events (A) as shown in supplemental The definition of T2DM was treatment with 1) diet only, 2) oral hypoglycemic agents only, or 3) insulin only or combined with oral agents, and onset age of diabetes ≥40 years Scottish Care InformationDiabetes database T2DM was defined using an algorithm which uses information from the clinician recorded diabetes type, prescription data (use of and timing of sulphonylureas and insulin) and age at diagnosis. SMART 36 A referral diagnosis of T2DM, self-reported T2DM, a fasting serum glucose ≥7.0 mmol/L at inclusion with initiation of glucose lowering treatment within one year, or the use of oral anti-hyperglycemic agents or insulin at baseline. Participants with known type 1 diabetes mellitus were excluded. EPIC-NL 28 Diagnosis of T2DM was self-reported at baseline. ACCORD 37 1) Symptoms of diabetes plus casual plasma glucose concentration ≥11.1 mmol/l. Casual was defined as any time of day without regard to time since last meal. The classic symptoms of T2DM include polyuria, polydipsia, and unexplained weight loss for ≥3 months. 2) Fasting plasma glucose ≥7.0 mmol/l. Fasting is defined as no caloric intake for at least 8 h for ≥3 months. 3) Stable diabetes therapy for >3 months. 4) An HbA1c level 7.5%-11% more than 3 months before randomization. Outcome evaluation: During follow-up, people were asked biannually to complete a standardized questionnaire on hospital admissions and outpatient clinic visits. If a vascular event was reported, hospital discharge letters and results of laboratory and radiology examinations were collected. Death was reported by relatives of the participant, the general practitioner or the treating specialist. All possible events were independently evaluated by three members of the endpoint committee, comprising physicians from different clinical departments. Myocardial infarction: Fatal and non-fatal myocardial infarction, characterized by at least two of the following criteria: 1. Chest pain for at least 20 minutes not disappearing after administration of nitrates 2. ST-elevation >1 mm in two following leads or a left bundle branch block on the ECG * 3. CK elevation of at least two times the normal value of CK and an MB-fraction >5% of the total CK Stroke: Relevant clinical features which have caused an increase in handicap of at least one grade on the modified Rankin scale, accompanied by a fresh infarct on a repeat CT scan. Cardiovascular mortality: -Sudden death: unexpected cardiac death occurring within 1 hour after onset of symptoms or within 24 hours given convincing circumstantial evidence -Death from ischemic stroke -Death from congestive heart failure -Death from myocardial infarction -Death from rupture of abdominal aortic aneurysm -Vascular death from other cause, i.e. sepsis following stent placement EPIC-NL 28 Outcome evaluation: Vital status was identified using the municipal population register with a loss-to-follow-up of 2.6%. For participants who died, information on Outcome evaluation: Outcomes were adjudicated by a central committee whose members were unaware of study-group assignments on the basis of predefined criteria. Myocardial infarction: The diagnosis of MI is based on the occurrence of a compatible clinical syndrome associated with diagnostic elevation of cardiac enzymes (ie, an increase in troponin T or troponin I to a level indicating myonecrosis and/or an increase in creatine kinase-myocardial band to a level more than twice the upper limit of normal). Q-wave MI is defined as the development of new significant Q waves. Silent MI is diagnosed when new (compared with the previous 12-lead electrocardiogram) significant Q waves are detected by surveillance electrocardiography performed every 2 years and at study end in all participants. Stroke: Stroke is diagnosed by a focal neurologic deficit that lasts >24 hours, associated with evidence of brain infarction or hemorrhage by computed tomography, MRI, or autopsy. Cardiovascular mortality: Cardiovascular causes of death include fatal MI, congestive heart failure, documented arrhythmia, death after invasive cardiovascular interventions, death after noncardiovascular surgery, fatal stroke, unexpected death presumed to be due to ischemic CVD occurring <24 hours after the onset of symptoms, and death due to other vascular diseases (eg, pulmonary emboli, abdominal aortic aneurysm rupture). ADVANCE Outcome evaluation: Each possible study endpoint was reviewed by at least two members of an independent Endpoint Committee blinded tot the study treatments following standardized study criteria, definitions and algorithms. Myocardial infarction: Non-fatal (including silent) myocardial infarction Stroke: Any stroke Cardiovascular mortality: Death due to any cardiovascular disease (not further specified) ALLHAT
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Outcome evaluation: The diagnosis of an endpoint was classified by the physicianinvestigator at the clinical site based on death certificates or hospital discharge summaries. For a random 10% subset of hospitalized (fatal and nonfatal) myocardial infarctions and strokes, the Clinical Trials Center will request more detailed information. For this subset, in hospital ECGs and enzyme levels (for myocardial infarctions), and neurologists' reports and computed tomography (CT) or magnetic resonance imaging (MRI) reports (for strokes) will be evaluated by the study Endpoints Committee and the accuracy of the discharge diagnoses assessed. Myocardial infarction: Non-fatal myocardial infarction based on hospital discharge summaries classified by the physician investigator. Stroke: Non-fatal stroke based on hospital discharge summaries classified by the physician investigator. Cardiovascular mortality: Any death classified by the physician-investigator as caused due to cardiovascular disease. Age-specific baseline survivals for centered continues variables with a systolic blood pressure of 140 mmHg, BMI of 30 kg/m², HbA1c of 50 mmol/l, non-HDL-c of 3.8 mmol/l, and eGFR of 80 ml/min. *Based on Cox proportional hazard function A for cardiovascular disease. **Based on Cox proportional hazard function B for non-cardiovascular mortality
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